› Forums › General Melanoma Community › I ntranssit treatments.
- This topic has 3 replies, 1 voice, and was last updated 11 years, 9 months ago by walesgirl.
- Post
-
- August 22, 2012 at 3:19 am
The management of in-transit metastases is challenging, since the treatments and extent of disease vary greatly based on the number, depth, location, and distribution of lesions, and on their biological behavior. A number of different treatment options exist, but there is no level 1 evidence to guide clinical decision-making. Herein we present our institutional treatment algorithm, which allows for individualization based on the patient's presentation.
The management of in-transit metastases is challenging, since the treatments and extent of disease vary greatly based on the number, depth, location, and distribution of lesions, and on their biological behavior. A number of different treatment options exist, but there is no level 1 evidence to guide clinical decision-making. Herein we present our institutional treatment algorithm, which allows for individualization based on the patient's presentation.
In-Transit Melanoma: An Individualized Approach
By Travis E. Grotz, MD1, Aaron S. Mansfield, MD2,3, Lisa A. Kottschade, CNP2,3, Lori A. Erickson, MD4, Lori A. Erickson, MD5, Svetomir N. Markovic, MD, PhD2,3, James W. Jakub, MD1 | December 30, 2011
- Replies
- You must be logged in to reply to this topic.